Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.

You may also be interested in...



Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations

The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.

Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations

The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.

Hospital Access, Reimbursement Slowing Effient Uptake, Execs Say

It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel